Deals In Depth: October 2017
Executive Summary
Eli Lilly made a big commitment to immuno-oncology with its $1.8 billion deal for CureVac's mRNA vaccines. Amneal and Impax merged, creating the fifth-largest generics company in the US. Billion-dollar aggregates were reached in FOPOs, debt, and late-stage venture pharma financing.